PriceTargets.com logo

Fortrea - FTRE Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $29.00
  • Forecasted Upside: 3.83%
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$27.93 As of 09/21/2023 06:18 PM ET
▼ -0.92 (-3.19%)

This chart shows the closing price for FTRE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fortrea Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FTRE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FTRE

Analyst Price Target is $29.00
▲ +3.83% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Fortrea in the last 3 months. The average price target is $29.00, with a high forecast of $31.00 and a low forecast of $27.00. The average price target represents a 3.83% upside from the last price of $27.93.

This chart shows the closing price for FTRE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Reduce

The current consensus among 2 contributing investment analysts is to reduce stock in Fortrea. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/29/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/24/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/21/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/20/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/14/2023Evercore ISIInitiated CoverageInline$31.00Low
8/15/2023BarclaysInitiated CoverageEqual Weight$29.00Low
8/7/2023Bank of AmericaInitiated CoverageUnderperform$27.00Low
(Data available from 9/21/2018 forward)

News Sentiment Rating

0.51 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2023
  • 2 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023

Current Sentiment

  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Fortrea logo
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. It offers phase I-IV clinical trial management, clinical pharmacology, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. is based in Durham, North Carolina.
Read More

Today's Range

Now: $27.93
Low: $27.81
High: $28.77

50 Day Range

MA: $29.13
Low: $25.11
High: $33.79

52 Week Range

Now: $27.93
Low: $24.92
High: $37.30

Volume

2,004,738 shs

Average Volume

2,077,690 shs

Market Capitalization

$2.48 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Fortrea?

The following Wall Street research analysts have issued stock ratings on Fortrea in the last twelve months: Bank of America Co., Barclays PLC, and Evercore ISI.
View the latest analyst ratings for FTRE.

What is the current price target for Fortrea?

3 Wall Street analysts have set twelve-month price targets for Fortrea in the last year. Their average twelve-month price target is $29.00, suggesting a possible upside of 3.8%. Evercore ISI has the highest price target set, predicting FTRE will reach $31.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $27.00 for Fortrea in the next year.
View the latest price targets for FTRE.

What is the current consensus analyst rating for Fortrea?

Fortrea currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for FTRE.

What other companies compete with Fortrea?

Other companies that are similar to Fortrea include RadNet, Veracyte, Guardant Health, Fulgent Genetics and Viridian Therapeutics. Learn More about companies similar to Fortrea.

How do I contact Fortrea's investor relations team?

Fortrea's physical mailing address is 8 Moore Drive, Durham, NC 27709, United States, . The company's listed phone number is 877-495-0816. The official website for Fortrea is www.fortrea.com. Learn More about contacing Fortrea investor relations.